Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the number of glioblastoma patients who are offered whole genome sequencing.

Genomic testing for glioblastoma is included in the National Genomic Test Directory. Testing can be delivered using a range of technologies, including whole genome sequencing or Next Generation Sequencing technology (large cancer gene panels) to ensure that a patient receives the most appropriate genomic testing depending on their individual circumstances. Anyone who meets the eligibility criteria outlined in the National Genomic Test Directory will be able to access this genomic testing.

In addition, glioblastomas are one of four cancer indications included in an innovative £26 million programme, led by Genomics England in partnership with the National Health Service, to evaluate cutting-edge genomic sequencing technology to improve the accuracy and speed of cancer diagnosis.

Genomics England are also collaborating with a lead researcher to support research into glioblastomas through the Brain Matrix study. Patients who have consented to this study will have whole genome sequencing performed via the NHS Genomic Medicine Service. Further information about the study is available at the following link:

https://www.thebraintumourcharity.org/media-centre/news/research-news/brain-matrix-pioneering-research-to-improve-treatments-for-gliomas/